OR WAIT null SECS
CDMO predicts that its facilities can now potentially produce over $400 million in annual revenue.
Avid Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), has completed construction of current good manufacturing practice (cGMP) manufacturing suites within its new, cell and gene therapy (CGT) development and cGMP manufacturing facility as scheduled. The suites are currently undergoing final environmental monitoring and performance qualification.
With the completion of this latest and final expansion project, Avid estimates that its combined facilities now have a potential total revenue generating capacity of up to approximately $400 million annually.
The 53,000 square-foot CGT development and manufacturing facility will support early-stage development through commercial manufacturing and is located in Orange County, CA, just five miles from Avid’s mammalian development and manufacturing operations; it will have the capability to produce suspension culture batches of up to 3,000 liters, as well as adherent cultures utilizing fixed bed bioreactors. The recently completed manufacturing suites join the CGT facility’s analytical and process development labs, which were launched last year.
“Over the past few years, we have implemented a strategic expansion plan designed to grow both our capacity and capabilities to align with the demands of the evolving biopharmaceutical market. With the completion of our CGT facility and launch of its cGMP manufacturing suites, we have now completed all phases of that expansion plan and find ourselves strongly positioned to meet the needs of our current and future customers,” comments Nick Green, president and CEO of Avid Bioservices. “We look forward to engaging with customers and offering them the full range of capabilities necessary to serve their needs along with Avid’s significant experience of operating cGMP-compliant facilities.”